Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medifast (MED) Gross Margin (2016 - 2025)

Medifast (MED) has disclosed Gross Margin for 16 consecutive years, with 69.43% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 470.0% year-over-year to 69.43%, compared with a TTM value of 71.33% through Dec 2025, down 247.0%, and an annual FY2025 reading of 71.33%, down 247.0% over the prior year.
  • Gross Margin was 69.43% for Q4 2025 at Medifast, roughly flat from 69.52% in the prior quarter.
  • Across five years, Gross Margin topped out at 75.39% in Q3 2024 and bottomed at 69.27% in Q4 2022.
  • Average Gross Margin over 5 years is 72.57%, with a median of 72.82% recorded in 2024.
  • The sharpest move saw Gross Margin skyrocketed 474bps in 2023, then plummeted -587bps in 2025.
  • Year by year, Gross Margin stood at 73.65% in 2021, then decreased by -6bps to 69.27% in 2022, then grew by 7bps to 74.01% in 2023, then grew by 0bps to 74.13% in 2024, then dropped by -6bps to 69.43% in 2025.
  • Business Quant data shows Gross Margin for MED at 69.43% in Q4 2025, 69.52% in Q3 2025, and 72.61% in Q2 2025.